newsfilter
← Earnings
Earnings Releases·

Teva Pharmaceutical Industries Ltd. — Third Quarter 2026 Earnings Summary

  • **Financial Results:** Q3 2026 revenue declined 2% year-over-year to $4.4 billion, while non-GAAP diluted EPS rose 10% to $0.86; adjusted EBITDA increased 7% to $1.5 billion, and free cash flow reached approximately $0.5 billion.
  • **Guidance & Outlook:** The company raised full-year 2026 revenue guidance to $16.7–$17.0 billion and non-GAAP EPS guidance to $1.92–$2.11, driven by strong growth in key innovative brands AUSTEDO, AJOVY, and UZEDY.
  • **Strategic & Capital Actions:** Teva achieved investment-grade credit ratings and refinanced approximately $4.9 billion in debt, targeting a 30% non-GAAP operating income margin and two times debt leverage by end-2027.
  • **Portfolio Developments:** The biosimilars business is projected to exceed $0.8 billion in 2026 revenue, one year ahead of schedule, while the company initiated a sales process to divest its API business and acquired BXCL-501 for FDA review.
Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic